<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2312200357
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EPIVIR 150MG F.C TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LAMIVUDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        336.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXO OPERATION" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXO OPERATION
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AF05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Epivir is used to treat HIV (human immunodeficiency virus) infection in adults and children.</strong></p><p>The active ingredient in Epivir is lamivudine. Epivir is a type of medicine known as an anti-retroviral. It belongs to a group of medicines called <em>nucleoside analogue reverse transcriptase inhibitors </em>(<em>NRTIs</em>).</p><p>&nbsp;</p><p>Epivir does not completely cure HIV infection; it reduces the amount of virus in your body, and keeps it at a low level. It also increases the CD4 cell count in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.</p><p>&nbsp;</p><p>Not everyone responds to treatment with Epivir in the same way. Your doctor will monitor the effectiveness of your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Epivir:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are<strong> allergic</strong> to<strong> </strong>lamivudine or any of the other ingredients of this medicine (<em>listed in Section 6</em>)<em>.</em></p><p><strong>Check with your doctor</strong> if you think this applies to you.</p><p>&nbsp;</p><p><strong>Take special care with Epivir</strong></p><p>Some people taking Epivir or other combination treatments for HIV are more at risk of serious side effects. You need to be aware of the extra risks:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had<strong> liver disease,</strong> including hepatitis B or C (if you have hepatitis B infection, do not stop Epivir without your doctor&rsquo;s advice, as your hepatitis may come back)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are seriously<strong> overweight</strong> (especially if you are a woman)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you or your child has a kidney problem</strong>, your dose may be altered.</p><p><strong>Talk to your doctor if any of these apply to you</strong>. You may need extra check-ups, including blood tests, while you are taking your medicine. <strong>See Section 4 for more information</strong>.</p><p><strong>&nbsp;</strong></p><p><strong>Look out for important symptoms</strong></p><p>Some people taking medicines for HIV infection develop other conditions, which can be serious. You need to know about important signs and symptoms to look out for while you are taking Epivir.</p><p><strong>Read the information &lsquo;Other possible side effects of combination therapy for HIV&rsquo; in Section&nbsp;4 of this leaflet</strong>.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Epivir</strong></p><p><strong>Tell your doctor or pharmacist if you are taking any other medicines</strong>, or if you have taken any recently, including herbal medicines or other medicines you bought without a prescription.</p><p>Remember to tell your doctor or pharmacist if you begin taking a new medicine while you are taking Epivir.</p><p>&nbsp;</p><p><strong>These medicines should not be used with Epivir:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines containing lamivudine, (used to treat <strong>HIV infection </strong>or <strong>hepatitis B infection</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; emtricitabine (used to treat <strong>HIV infection</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high doses of <strong>co-trimoxazole</strong>, an antibiotic</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cladribine (used to treat hairy cell leukaemia).</p><p><strong>Tell your doctor</strong> if you are being treated with any of these.</p><p>&nbsp;</p><p><strong>Pregnancy</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f4be209e-deb5-437e-93a2-04a7058ec94f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you are pregnant, if you become pregnant, or are planning to become pregnant, talk to your doctor about the risks and benefits to you and your baby of taking Epivir.</p><p>Epivir and similar medicines may cause side effects in unborn babies. If you have taken Epivir during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>Breast-feeding is <strong>not recommended</strong> in women living with HIV because HIV infection can be passed on to the baby in breast milk.</p><p>A small amount of the ingredients in Epivir can also pass into your breast milk.</p><p>If you are breast-feeding, or thinking about breast-feeding, you should<strong> discuss it with your doctor as soon as possible</strong>.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Epivir is unlikely to affect your ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Epivir contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor or pharmacist has told you</strong>. Check with your doctor or pharmacist if you are not sure.</p><p>Swallow the tablets, with some water. Epivir can be taken with or without food.</p><p>If you cannot swallow the tablets whole, you may crush and combine them with a small amount of food or drink, and take all the dose immediately.</p><p>&nbsp;</p><p><strong>Stay in regular contact with your doctor</strong></p><p>Epivir helps to control your condition. You need to keep taking it every day to stop your illness getting worse. You may still develop other infections and illnesses linked to HIV infection.</p><p><strong>Keep in touch with your doctor, and do not stop taking Epivir</strong> without your doctor&rsquo;s advice.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p><strong>Adults, adolescents and children who weigh at least 25&nbsp;kg:</strong></p><p><strong>The usual dose of Epivir is 300&nbsp;mg</strong> <strong>a day</strong>.<strong> </strong>This can be taken as either one 150 mg tablet twice a day (leaving approximately 12 hours between each dose), or two 150 mg tablets once a day as advised by your doctor.</p><p>&nbsp;</p><p><strong>Children weighing at least 20 kg and less than 25&nbsp;kg:</strong></p><p><strong>The usual dose of Epivir is 225 mg a day.</strong> This can be given as 75 mg (half a 150 mg tablet) in the morning and 150 mg (one whole 150 mg tablet) in the evening, or 225 mg (one and a half 150 mg tablets) once a day as advised by your doctor.</p><p>&nbsp;</p><p><strong>Children weighing at least 14 kg and less than 20&nbsp;kg:</strong></p><p><strong>The usual dose of Epivir is 150 mg a day. </strong>This can be given as 75 mg (half a 150 mg tablet) twice a day (leaving approximately 12 hours between each dose), or 150 mg (one 150 mg tablet) once a day as advised by your doctor.</p><p>An oral solution is also available for the treatment of children over 3 months of age, or for people who need a lower dose than usual, or who cannot take tablets.</p><p>&nbsp;</p><p><strong>If you or your child has a kidney problem</strong>, your dose may be altered. <!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE vault_nd_05e34a02-e299-4692-a5e8-dbed7f38d65d
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Talk to your doctor </strong>if this applies to you or your child.<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1533300e-e164-420d-9714-c7abb4dd7cc4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>If you take more Epivir than you should</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_1e47605d-c430-488f-9f8f-3345b9a9de43 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you take too much Epivir, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advice. If possible, show them the Epivir pack.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Epivir</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3a187a5c-64d5-4236-b0a7-47fbef86b3d6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you forget to take a dose, take it as soon as you remember. Then continue your treatment as before. Do not take a double dose to make up for a forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p><p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, but not everyone gets them.</p><p>&nbsp;</p><p>When you are being treated for HIV, it can be hard to tell whether a symptom is a side effect of Epivir or other medicines you are taking, or an effect of the HIV disease itself. <strong>So it is very important to talk to your doctor about any changes in your health</strong>.</p><p>&nbsp;</p><p><strong>As well as the side effects listed below for Epivir</strong>, other conditions can develop during combination therapy for&nbsp;HIV.</p><p>It is important to read the information later in this section under &lsquo;Other possible side effects of combination therapy for&nbsp;HIV&rsquo;.</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects</strong></p><p>These may affect<strong> up to 1 in 10</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (<em>vomiting</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pains</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, lack of energy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (high temperature)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general feeling of being unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain and discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in sleeping (<em>insomnia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritated or runny nose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss (<em>alopecia</em>).</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon side effects</strong></p><p>These may affect<strong> up to 1 in 100</strong> people:</p><p>Uncommon side effects that may show up in blood tests are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in the number of cells involved in blood clotting (<em>thrombocytopenia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a low red blood cell count (<em>anaemia</em>) or low white blood cell count (<em>neutropenia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in the level of liver enzymes.</p><p><strong>&nbsp;</strong></p><p><strong>Rare side effects</strong></p><p>These may affect <strong>up to 1 in 1000</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reaction causing swelling of the face, tongue or throat which may cause difficulty in swallowing or breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas (<em>pancreatitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breakdown of muscle tissue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (<em>hepatitis</em>).</p><p>A rare side effect that may show up in blood tests is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in an enzyme called amylase.</p><p><strong>&nbsp;</strong></p><p><strong>Very rare side effects</strong></p><p>These may affect <strong>up to 1 in 10,000</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactic acidosis (excess lactic acid in the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness of the arms, legs, hands or feet.</p><p>A very rare side effect that may show up in blood tests is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a failure of the bone marrow to produce new red blood cells<em> (pure red cell aplasia)</em>.</p><p>&nbsp;</p><p><strong>If you get side effects</strong></p><p><strong>Tell your doctor or pharmacist</strong> if any of the side effects gets severe or troublesome, or if you notice any side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>Other possible side effects of combination therapy for HIV</strong></p><p>Combination therapy including Epivir may cause other conditions to develop during HIV treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Old infections may flare up</strong></p><p>People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body&rsquo;s immune system becoming stronger, so that the body starts to fight these infections.</p><p>In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.</p><p>&nbsp;</p><p>If you get any symptoms of infection while you are taking Epivir:</p><p><strong>Tell your doctor immediately</strong>. Do not take other medicines for the infection without your doctor&rsquo;s advice.</p><p>&nbsp;</p><p><strong>You may have problems with your bones</strong></p><p>Some people taking combination therapy for HIV develop a condition called <em>osteonecrosis</em>. With this condition, parts of the bone tissue die because of reduced blood supply to the bone. People may be more likely to get this condition:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they have been taking combination therapy for a long time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are also taking anti-inflammatory medicines called corticosteroids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they drink alcohol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if their immune systems are very weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are overweight.</p><p><strong>Signs of osteonecrosis include:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness in the joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aches and pains (especially in the hip, knee or shoulder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty moving.</p><p>If you notice any of these symptoms:</p><p><strong>Tell your doctor</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c0d52c8d-41f9-4068-bb15-d98811173536 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Do not use this medicine after the expiry date which is stated on the carton.<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d86541a5-79b0-4f9e-be1b-c8a7fa5cb015 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Store Epivir below 30<sup>&deg;</sup>C.<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_c646c47d-5eae-43b6-a64d-e98238a5ede8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is lamivudine.</p><p>&nbsp;</p><p>The tablets also contain the following other ingredients:</p><p>Tablet core: microcrystalline cellulose, sodium starch glycollate, magnesium stearate.</p><p>Film coat: Hypromellose (E464), titanium dioxide, macrogol, polysorbate 80.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Epivir 150 mg are white, diamond shaped, scored, film-coated tablets, engraved with the code ‘GXCJ7’ on both sides.  

Not all pack sizes are marketed in every country. 

Epivir is trademark owned by or licensed to the ViiV Healthcare group of companies. 
©2023 ViiV Healthcare group of companies. All rights reserved 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia</p><p>*member of the GlaxoSmithKline group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised on  21 April 2023.
Version Number UK_17

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>يُستخدم إيپيڤير لعلاج العدوى بفيروس نقص المناعة البشري لدى البالغين والأطفال.</strong></p><p dir="RTL">المكوِّن الفعَّال في إيپيڤير هو &rlm;‫لاميڤودين. يُعد إيپيڤير نوعًا من الأدوية المعروفة باسم مضادات الفيروسات الرجعية. وينتمي إلى فئة من الأدوية تُسمى <em>مثبطات إنزيم المنتسخة العكسية النيوكليوزيدية</em> (<em>NRTI</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يقضي إيپيڤير على عدوى فيروس نقص المناعة البشري بشكل كامل، بل يقلل من انتشار الفيروس في الجسم ويبقي مستوياته منخفضة. كما يعمل على زيادة عدد خلايا CD4 (كتلة التمايز 4) في الدم. وخلايا CD4 (كتلة التمايز 4) هي نوع من خلايا الدم البيضاء التي لها دور مهم في مساعدة الجسم على مكافحة العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تختلف استجابات المرضى للعلاج بدواء إيپيڤير. سوف يراقب طبيبك مدى فعالية علاجك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم تناول إيپيڤير في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية</strong> من لاميڤودين أو أي من مكوّنات الدواء الأخرى (<em>المذكورة في القسم 6</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استشر طبيبك</strong> إذا كنت تعتقد أن هذه الحالة تنطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخي الحذر البالغ عند استخدام إيپيڤير</strong></p><p dir="RTL">بعض المرضى الذين يتناولون إيپيڤير أو غيره من العلاجات المركبة لفيروس نقص المناعة البشري يكونون أكثر عُرضة للإصابة بالآثار الجانبية الخطيرة. ويجب أن تضع في اعتبارك المخاطر الأخرى التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت سابقًا <strong>بمرض في الكبد</strong>، بما في ذلك التهاب الكبد B أو C (إذا كنت مصابًا بعدوى التهاب الكبد B، فلا تتوقف عن تناول إيپيڤير بدون استشارة طبيبك؛ إذ قد يعاودك التهاب الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>زيادة الوزن</strong> المفرطة (على الأخص إذا كنتِ امرأة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني أنت أو طفلك من مشكلة في الكلى</strong>، فربما يعدّل الطبيب الجرعة.</p><p dir="RTL"><strong>استشر طبيبك إذا كانت لديك أي من الحالات سالفة الذكر.</strong> قد تحتاج إلى إجراء المزيد من الفحوصات، بما في ذلك فحوصات الدم، أثناء تناول الدواء. <strong>راجع القسم 4 لمعرفة مزيد من المعلومات</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض مهمة يجب الانتباه لها</strong></p><p dir="RTL">يصاب بعض الأشخاص الذين يتناولون أدويةً لعلاج &rlm;‫عدوى فيروس نقص المناعة البشري بحالات أخرى يمكن أن تكون خطيرة. عليك معرفة معلومات حول العلامات والأعراض المهمة التي ينبغي الانتباه لها أثناء تناول إيپيڤير.</p><p dir="RTL"><strong>اقرأ المعلومات الموجودة في &quot;الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشري&quot; في القسم 4 من هذه النشرة</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وإيپيڤير</strong></p><p dir="RTL"><strong>قم بإبلاغ الطبيب أو الصيدلي إذا كنت تتناول حاليًا</strong>، أو تناولت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية العشبية أو الأدوية الأخرى التي اشتريتها بدون وصفة طبية.</p><p dir="RTL">تذكّر إبلاغ الطبيب أو الصيدلي إذا كنت ستبدأ في تناول دواء جديد أثناء تناولك إيپيڤير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عدم تناول الأدوية التالية مع إيپيڤير:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية (السائلة عادةً) التي تحتوي على السوربيتول أو غيره من الكحولات السكرية (مثل زيليتول أو مانيتول أو لاكتيتول أو مالتيتول)، إذا كان تناولها يتم بشكل منتظم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تحتوي على لاميڤودين (المُستخدمة في علاج <strong>عدوى نقص المناعة البشري</strong> أو <strong>عدوى إلتهاب الكبد </strong><strong>B</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمتريسيتابين (المُستخدَم في علاج <strong>عدوى فيروس نقص المناعة البشري</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعات كبيرة من المضاد الحيوي <strong>كوتريموكسازول</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلادريبين (المُستخدَم في علاج ابيضاض الدم مشعر الخلايا).</p><p dir="RTL"><strong>أخبر طبيبك</strong> إذا كنت تُعالَج بأي من هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>DOCVARIABLE</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>VAULT_ND_12490cd7-6f1a-4ee6-a3a4-ba6d740c58e8 \* MERGEFORMAT</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا كنتِ حاملاً في الوقت الحالي أو إذا أصبحتِ حاملاً أو كنتِ تخططين للحمل، فعليكِ التحدث إلى طبيبكِ بشأن مخاطر تناول إيپيڤير عليكِ أنتِ وطفلكِ وفوائده لكل منكما.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ربما يتسبب إيپيڤير والأدوية المماثلة في حدوث آثار جانبية للأجنة. إذا كنتِ قد تناولتي إيپيڤير أثناء حملكِ، فقد يطلب طبيبكِ إجراء فحوصات دم دورية وغيرها من الاختبارات التشخيصية لمتابعة نمو طفلكِ. في حالة الأطفال الذين تناولت أمهاتهم مثبطات إنزيم المنتسخة العكسية النيوكليوزيدية (NRTI) أثناء الحمل، كانت فائدة الوقاية من الإصابة بفيروس نقص المناعة البشري أكبر من خطر الإصابة بآثار جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL"><strong>لا ينصح</strong> بالرضاعة الطبيعية للنساء المتعايشات مع فيروس نقص المناعة البشرية، لأن عدوى فيروس نقص المناعة البشري يمكن أن تنتقل إلى الطفل عن طريق لبن الأم.</p><p dir="RTL">يمكن أيضًا أن تنتقل كمية بسيطة من مكوّنات إيپيڤير إلى لبن الأم.</p><p dir="RTL">إذا كنتِ ترضعين طفلكِ رضاعة طبيعية أو تفكرين في ذلك: <strong>يجب عليكِ استشارة طبيبكِ المعالج في أقرب وقت ممكن.</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يؤثر إيپيڤير في قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إيپيڤير</strong><strong> </strong><strong>يحتوى على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من واحد ملي مول من الصوديوم (23 ملجم) لكل قرص، مما يعني أنه في الأساس &quot;خالي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تناول هذا الدواء دائمًا حسب تعليمات الطبيب أو الصيدلي بالضبط</strong><strong>.</strong> وينبغي لك مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدًا من هذا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ابتلع القرص مع بعض الماء. يمكن تناول إيپيڤير مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تستطع ابتلاع القرص بالكامل، يمكنك سحقه وخلطه بمقدار بسيط مع أي من الأطعمة أو المشروبات وتناول الجرعة كلها على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تواصل باستمرار مع طبيبك</strong></p><p dir="RTL">يساعد إيپيڤير في التحكم في حالتك الصحية. ويجب عليك تناوله يوميًا لمنع تفاقم المرض. وما زال من الممكن أن تصاب بحالات عدوى وأمراض أخرى ترتبط بعدوى فيروس نقص المناعة البشري.</p><p dir="RTL"><strong>تواصل مع طبيبك باستمرار، ولا تتوقف عن تناول </strong>إيپيڤير بدون استشارته أولاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><strong>البالغون والمراهقون والأطفال الذين يبلغ وزنهم 25 كجم على الأقل:</strong></p><p dir="RTL"><strong>الجرعة المعتادة من إيپيڤير هي 300&nbsp;ملجم</strong><strong> في اليوم.</strong> ويمكن تناولها على هيئة قرص واحد 150 ملجم يؤخذ مرتين في اليوم (بفاصل بين كل جرعة يقرب من 12 ساعة) أو قرصين 150 ملجم مرة واحدة في اليوم، حسب تعليمات الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال الذين تتراوح أوزانهم بين 20 كجم بحد أدنى ولا تزيد عن 25 كجم:</strong></p><p dir="RTL"><strong>الجرعة المعتادة من إيپيڤير هي 225&nbsp;ملجم في اليوم.</strong> ويمكن تناولها على هيئة 75 ملجم (نصف قرص تركيز 150 ملجم) في الصباح و150 ملجم (قرص كامل تركيز 150 ملجم) في المساء، أو 225 ملجم (قرص ونصف تركيز 150 ملجم) مرة واحدة في اليوم، حسب تعليمات الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال الذين تتراوح أوزانهم بين 14 كجم بحد أدنى ولا تزيد عن 20 كجم:</strong></p><p dir="RTL"><strong>الجرعة المعتادة من إيپيڤير هي 150&nbsp;ملجم في اليوم.</strong> ويمكن تناولها على هيئة 75 ملجم (نصف قرص تركيز 150 ملجم) يؤخذ مرتين في اليوم (بفاصل بين كل جرعة يقرب من 12 ساعة) أو 150 ملجم (قرص واحد تركيز 150 ملجم) مرة واحدة في اليوم، حسب تعليمات الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر أيضًا محلول للتناول عن طريق الفم لعلاج الأطفال الذين تتجاوز أعمارهم 3 أشهر، أو لعلاج الأشخاص الذين يحتاجون إلى جرعة أقل من المعتاد، أو الذين لا يستطيعون تناول الأقراص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تعاني أنت أو طفلك من مشكلة في الكلى</strong>، فربما يعدّل الطبيب الجرعة.<!--[if supportFields]><span lang=AR-SA style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span> </span><span dir=LTR style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";color:black;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'>VAULT_ND_eae05272-1f08-494d-8fe9-2e3d856c194b \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&lrm;<strong>أبلغ الطبيب</strong> إذا كانت هذه الحالة تنطبق عليك أو طفلك.<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>VAULT_ND_0bab9ebd-2281-4fc5-820a-316d0ce19c9a \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";color:black;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من إيپيڤير</strong><!--[if supportFields]><b><span lang=AR-SA style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>DOCVARIABLE</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>VAULT_ND_3ec15027-9284-42f8-8ae1-dfbbb0b32671 \* MERGEFORMAT</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&lrm;في حالة تناول جرعة أكبر من اللازم من <strong>إ</strong>يپيڤير ، أبلغ الطبيب أو الصيدلي أو اتصل بقسم الطوارئ بأقرب مستشفى للحصول على استشارة إضافية. لو أمكن، أظهر لهم عبوة إيپيڤير.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة نسيان تناول جرعة إيپيڤير</strong><!--[if supportFields]><b><span lang=AR-SA style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>DOCVARIABLE</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>VAULT_ND_b1516670-b9af-4dfa-8572-d40ea1e2bc04 \* MERGEFORMAT</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
color:black;mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">في حالة نسيان تناول جرعة، يجب تناولها فور التذكر. ثم تابع العلاج كما في السابق. يجب عدم تناول جرعة مضاعفة لتعويض الجرعة الفائتة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أثناء علاج فيروس نقص المناعة البشري، قد تحدث زيادة في الوزن وفي مستويات شحوم الدم والجلوكوز. يتعلق ذلك -بشكل جزئي- باستعادة الصحة وأسلوب الحياة، أما في حالة زيادة شحوم الدم، فيعود أحيانًا السبب في زيادتها إلى أدوية فيروس نقص المناعة البشري نفسها. سوف يفحص الطبيب هذه التغيرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في آثار جانبية، ولكن لا يصاب بها جميع الأشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء العلاج من فيروس نقص المناعة البشري، قد يصعب تحديد ما إذا كان أي عَرض يطرأ هو أثر جانبي لتناول دواء إيپيڤير أو أي أدوية أخرى تتناولها، أم أثر لمرض فيروس نقص المناعة البشري ذاته. <strong>لذا، من المهم جدًا استشارة الطبيب عندما تطرأ أي تغيرات على صحتك</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاوةً على الآثار الجانبية الموضحة أدناه لدواء</strong><strong> إيپيڤير</strong>&lrm;، يمكن الإصابة ببعض الحالات الأخرى أثناء العلاج المركب لفيروس نقص المناعة البشري.</p><p dir="RTL">من المهم قراءة المعلومات الواردة لاحقًا في هذا القسم ضمن &quot;الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشري&quot;.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">يمكن أن تصيب <strong>شخصًا</strong> <strong>واحدًا بحد أقصى بين كل 10</strong> أشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب وفقدان الطاقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (ارتفاع درجة الحرارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور العام بالتوعك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم وانعدام الراحة في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم <em>(الأرق)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج أو سيلان الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر <em>(الثعلبة)</em>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong></p><p dir="RTL">يمكن أن تصيب <strong>شخصًا</strong> <strong>واحدًا بحد أقصى بين كل 100</strong> شخص:</p><p dir="RTL">الآثار الجانبية غير الشائعة التي قد تظهر في فحوصات الدم:</p><ul><li dir="RTL">انخفاض في عدد الخلايا التي تعمل على تجلط الدم <em>(قلة الصفيحات)</em></li><li dir="RTL">انخفاض في عدد خلايا الدم الحمراء <em>(فقر الدم)</em> أو انخفاض في عدد خلايا الدم البيضاء <em>(قلة العدلات)</em></li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستوى إنزيمات الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong></p><p dir="RTL">يمكن أن تصيب <strong>شخصًا</strong> <strong>واحدًا بحد أقصى بين كل</strong> 1000 شخص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية الخطيرة التي تسبب تورّم الوجه أو اللسان أو الحلق مما قد يؤدي إلى صعوبة البلع أو التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انحلال النسيج العضلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الكبدى<em> (التهاب الكبد)</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثر جانبي نادر قد يظهر في فحوصات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيم يُعرف باسم الأميلاز.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية النادرة جدًا</strong></p><p dir="RTL">يمكن أن تصيب <strong>شخصًا</strong> <strong>واحدًا بحد أقصى بين كل</strong> 10000 شخص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحُماض اللاكتيكي (زيادة مستويات حمض اللاكتيك في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو خدَر في الذراعين أو الساقين أو اليدين أو القدمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثر جانبي نادر جدًا قد يظهر في فحوصات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل النخاع العظمي في إنتاج خلايا دم حمراء جديدة <em>(عدم تنسج خلايا الدم الحمراء النقية)</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة الإصابة بالآثار الجانبية</strong></p><p dir="RTL"><strong>أخبر الطبيب أو الصيدلي</strong> في حال تفاقم أي من الآثار الجانبية أو تسببها في حدوث إزعاج، أو إذا لاحظت أي آثار جانبية غير واردة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشري</strong></p><p dir="RTL">قد يتسبب العلاج المركب الذي يشتمل على إيپيڤير في الإصابة ببعض الحالات الأخرى أثناء علاج فيروس نقص المناعة البشري.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>احتمال احتدام الإصابات السابقة</strong></p><p dir="RTL">بالنسبة للمرضى المصابين بحالة متقدمة من عدوى فيروس نقص المناعة البشري (الإيدز)، يكون جهازهم المناعي ضعيفًا، مما يجعلهم أكثر عرضة للإصابة بحالات عدوى خطيرة (حالات العدوى الانتهازية). وعند بدء العلاج، ربما يلاحظ هؤلاء المرضى احتدام حالات العدوى القديمة مسببةً ظهور علامات وأعراض الالتهاب. ومن المحتمل أن يكون سبب ظهور هذه الأعراض ازدياد قوة الجهاز المناعي بالجسم لتمكينه من بدء مكافحة حالات العدوى هذه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">بالإضافة إلى حالات العدوى الانتهازية، قد تحدث اضطرابات المناعة الذاتية أيضًا (وهي حالة تحدث عندما يهاجم الجهاز المناعي أنسجة الجسم السليمة) بعد بدء تناول الأدوية الخاصة بعلاج عدوى فيروس نقص المناعة البشري. وربما تحدث اضطرابات المناعة الذاتية بعد عدة أشهر من بدء العلاج. إذا لاحظت أي أعراض للعدوى أو غيرها من الأعراض، مثل ضعف العضلات، أو ضعف يبدأ في اليدين والقدمين ويتحرك لأعلى نحو جذع الجسم، أو الخفقان، أو الرعاش، أو فرط النشاط، فأبلغ الطبيب على الفور للحصول على العلاج اللازم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال ظهور أي من أعراض العدوى أثناء تناول إيپيڤير:</p><p dir="RTL"><strong>أخبر طبيبك فورًا</strong>. ولا تتناول أي أدوية أخرى لعلاج العدوى بدون استشارة الطبيب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد تكون لديك مشكلات في العظام</strong></p><p dir="RTL">يصاب بعض الأشخاص الذين يتناولون العلاج المركب لفيروس نقص المناعة البشري بحالة يُطلَق عليها <em>نخر العظام</em>. في هذه الحالة، تموت أجزاء من أنسجة العظام بسبب انخفاض تدفق الدم إلى العظام. تزداد احتمالية الإصابة بهذه الحالة لدى الأشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون علاجًا مركبًا لمدة طويلة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون الأدوية المضادة للالتهابات التي يُطلق عليها الستيرويدات القشرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون مشروبات كحولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يعانون من ضعف شديد في جهازهم المناعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يعانون من زيادة الوزن.</p><p dir="RTL"><strong>تشمل علامات نخر العظام:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع وآلام (وخاصة في الورك أو الركبة أو الكتف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الحركة.</p><p dir="RTL">عند ملاحظة أي من هذه الأعراض:</p><p dir="RTL"><strong>أخبر الطبيب</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب حفظ الدواء بعيدًا عن مرأى ومتناول الأطفال.<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'>VAULT_ND_f3eb077e-db7e-4d3e-beae-33cade8b14e4 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">يجب عدم استخدام هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن على العبوة الكرتونية.<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'>VAULT_ND_64582993-2d2e-4888-bfe4-15567fa11362 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">يجب تخزين إيپيڤير في درجة حرارة أقل من 30 درجة مئوية.<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'>VAULT_ND_21ce6496-58fc-4f69-9bd7-9f720f9f7d3a \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB;
mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&rlm;‫لا تتخلص من أي أدوية في مياه الصرف الصحي ولا المخلفات المنزلية. استشر الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. &rlm;‫فهذه الإجراءات من شأنها المساعدة على حماية البيئة.&rlm;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعَّالة بهذا الدواء هي لاميڤودين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي الأقراص أيضًا على المكوّنات الأخرى التالية:</p><p dir="RTL">لب القرص: سليلوز دقيق التبلور، جلايكولات نشاء الصوديوم، ستيرات المغنسيوم.</p><p dir="RTL">غلاف القرص: هيبرومليوز (E464)، ثاني أكسيد التيتانيوم، ماكروجول، بوليسوربات 80.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دواء إيپيڤير تركيز 150 ملجم عبارة عن أقراص مغلَّفة بيضاء محززة ماسية الشكل، منقوش على جانبيها الرمز &quot;GXCJ7&quot;.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا تتوفر بعض أحجام العبوات في بعض البلدان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>إيپيڤير</em>علامة تجاریة مملوكة &nbsp;أو مرخصة لمجموعة شركات ڤیڤ هيلثكير.</p><p dir="RTL">&copy; 2023 مجموعة شركات ڤيڤ هيلثكير. جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">ديلفارم بوزنان أسبولكا أكسيجنا، أولي. جرانڤالسكا 189، 60 - 322 بوزنان، بولندا</p><p dir="RTL"><strong>مالك التسويق المعتمد:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة* جدة، المملكة العربية السعودية</p><p dir="RTL">العنوان: صندوق بريد 22617 ، جدة 21416 ، المملكة العربية السعودية.</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ 21 ابريل 2023
رقم الإصدار: UK_17 

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Epivir 150 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Epivir 150 mg film-coated tablets

Each film-coated tablet contains 150 mg lamivudine. 

Excipient(s) with known effect: 
Each 150 mg tablet contains 0.378 mg sodium. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Epivir 150 mg film-coated tablets

Film-coated tablet

White, diamond shaped scored tablets engraved with “GX CJ7” on both faces.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epivir is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The therapy should be initiated by a physician experienced in the management of HIV infection.</p><p>&nbsp;</p><p>Epivir may be administered with or without food.</p><p>To ensure administration of the entire dose, the tablet(s) should ideally be swallowed without crushing.&nbsp;</p><p><em>&nbsp;</em></p><p>Epivir is also available as an oral solution for children over three months of age and who weigh less than 14 kg or for patients who are unable to swallow tablets (see section 4.4).</p><p>Patients changing between lamivudine oral solution and lamivudine tablets should follow the dosing recommendations that are specific for the formulation (see section 5.2)</p><p>&nbsp;</p><p>Alternatively, for patients who are unable to swallow tablets, the tablet(s) may be crushed and added to a small amount of semi-solid food or liquid, all of which should be consumed immediately (see section 5.2).</p><p><strong>&nbsp;</strong></p><p><em><u>Adults, adolescents and children (weighing at least 25 kg):<strong> </strong></u></em></p><p><strong><em>&nbsp;</em></strong></p><p>The recommended dose of Epivir is 300&nbsp;mg daily. This may be administered as either 150&nbsp;mg twice daily or 300&nbsp;mg once daily (see section 4.4).</p><p>&nbsp;</p><p><em><u>Children (weighing less than 25 kg):</u></em></p><p><em>&nbsp;</em></p><p>Dosing according to weight bands is recommended for Epivir tablets.</p><p><em><u>&nbsp;</u></em></p><p><em>Children weighing &ge; 20 kg to &lt;25 kg</em>:<em> </em>The recommended dose is 225 mg daily. This may be administered as either 75 mg (one-half of a 150 mg tablet) taken in the morning and 150 mg (one whole 150 mg tablet) taken in the evening, or 225 mg (one and a half 150 mg tablets) taken once daily<em>.</em></p><p><em>&nbsp;</em></p><p><em>Children weighing 14 to &lt; 20 kg</em>: The recommended dose is 150 mg daily. This may be administered as 75 mg (one-half of a 150 mg tablet) taken twice daily, or 150 mg (one whole 150 mg tablet) taken once daily.&nbsp;</p><p>&nbsp;</p><p><em>Children from three months of age: </em>It is recommended that the Epivir 150 mg scored tablet formulation is used and the corresponding recommended dosage instructions are followed.</p><p>&nbsp;</p><p><em>Children less than three months of age: </em>The limited data available are insufficient to propose specific dosage recommendations (see section 5.2).</p><p><em>&nbsp;</em></p><p>Patients changing from the twice daily dosing regimen to the once daily dosing regimen should take the recommended once daily dose (as described above) approximately 12 hours after the last twice daily dose, and then continue to take the recommended once daily dose (as described above) approximately every 24 hours. When changing back to a twice daily regimen, patients should take the recommended twice daily dose approximately 24 hours after the last once daily dose.</p><p>&nbsp;</p><p><em><u>Special populations:</u></em></p><p><em>&nbsp;</em></p><p><em>Older people:</em> No specific data are available; however, special care is advised in this age group due to age-associated changes such as the decrease in renal&nbsp;function and alteration of haematological parameters.</p><p><em>&nbsp;</em></p><p><em>Renal impairment: </em>Lamivudine concentrations are increased in patients with moderate&nbsp;-&nbsp;severe renal impairment due to decreased clearance.&nbsp; The dose should therefore be adjusted, using oral solution presentation of Epivir for patients whose creatinine clearance falls below 30&nbsp;ml/min (see tables).</p><p><strong>&nbsp;</strong></p><p><em>Dosing recommendations &ndash; Adults, adolescents and children (weighing at least 25 kg):</em></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Creatinine clearance<br />(ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>First dose</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&sup3;50</p></td><td style="vertical-align:top"><p>300 mg</p><p>or</p><p>150&nbsp;mg</p></td><td style="vertical-align:top"><p>300 mg once daily</p><p>or</p><p>150&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>30-&lt;50</p></td><td style="vertical-align:top"><p>150&nbsp;mg</p></td><td style="vertical-align:top"><p>150&nbsp;mg once daily</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&lt;30 As doses below 150 mg are needed the use of the oral solution is recommended</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15 to &lt;30</p></td><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>100 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>5 to &lt;15</p></td><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>50 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>&lt;5</p></td><td style="vertical-align:top"><p>50 mg</p></td><td style="vertical-align:top"><p>25 mg once daily</p></td></tr></tbody></table><p>&nbsp;</p><p>There are no data available on the use of lamivudine in children with renal impairment.&nbsp; Based on the assumption that creatinine clearance and lamivudine clearance are correlated similarly in children as in adults; it is recommended that the dosage in children with renal impairment be reduced according to their creatinine clearance by the same proportion as in adults. The Epivir 10&nbsp;mg/mL oral solution may be the most appropriate formulation to achieve the recommended dose in children with renal impairment aged at least 3 months and weighing less than 25kg.</p><p>&nbsp;</p><p><em>Dosing recommendations &ndash; Children aged at least 3 months and weighing less than 25 kg:</em></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>First dose</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&sup3;50</p></td><td style="vertical-align:top"><p>10 mg/kg</p><p>or</p><p>5&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>10 mg/kg once daily</p><p>or</p><p>5&nbsp;mg/kg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>30 to&lt;50</p></td><td style="vertical-align:top"><p>5&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>5&nbsp;mg/kg once daily</p></td></tr><tr><td style="vertical-align:top"><p>15 to &lt;30</p></td><td style="vertical-align:top"><p>5&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>3.3&nbsp;mg/kg once daily</p></td></tr><tr><td style="vertical-align:top"><p>5 to &lt;15</p></td><td style="vertical-align:top"><p>5&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>1.6&nbsp;mg/kg once daily</p></td></tr><tr><td style="vertical-align:top"><p>&lt;5</p></td><td style="vertical-align:top"><p>1.6&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>0.9&nbsp;mg/kg once daily</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Hepatic impairment:</em><strong> </strong>Data obtained in patients with moderate to severe hepatic impairment shows that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction. Based on these data, no dose adjustment is necessary in patients with moderate or severe hepatic impairment unless accompanied by renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epivir is not recommended for use as monotherapy.<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ed2596b5-483e-4d2e-9f3a-43ffb6d7dd52 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><em>Renal impairment:</em> In patients with moderate to severe renal impairment, the terminal plasma half-life of lamivudine is increased due to decreased clearance, therefore the dose should be adjusted (see section 4.2).</p><p><em>&nbsp;</em></p><p><em>Triple nucleoside therapy:</em> There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when lamivudine was combined with tenofovir disoproxil fumarate and abacavir as well as with tenofovir disoproxil fumarate and didanosine as a once daily regimen.</p><p><em>&nbsp;</em></p><p><em>Opportunistic infections:</em> Patients receiving Epivir or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with associated HIV diseases.</p><p><em>&nbsp;</em></p><p><em>Pancreatitis</em>: Cases of pancreatitis have occurred rarely. However it is not clear whether these cases were due to the antiretroviral treatment or to the underlying HIV disease. Treatment with Epivir should be stopped immediately if clinical signs, symptoms or laboratory abnormalities suggestive of pancreatitis occur.</p><p>&nbsp;</p><p><em>Mitochondrial dysfunction following exposure in utero:</em> Nucleoside and nucleotide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV-negative infants exposed <em>in utero</em> and/or post-natally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia). These events have often been transitory. Late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed <em>in utero</em> to nucleoside and nucleotide analogues, who presents with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.</p><p>&nbsp;</p><p><em>Weight and metabolic parameters: </em>An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and life style. For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.</p><p>&nbsp;</p><p><em>Immune Reactivation Syndrome:</em> In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and <em>Pneumocystis jirovecii</em> pneumonia (often referred to as PCP). Any inflammatory symptoms should be evaluated and treatment instituted when necessary.&nbsp; Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p>&nbsp;</p><p><em>Liver disease: </em>If lamivudine is being used concomitantly for the treatment of HIV and HBV, additional information relating to the use of lamivudine in the treatment of hepatitis B infection is available in the Zeffix SPC.</p><p><em>&nbsp;</em></p><p>Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events. In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.</p><p>&nbsp;</p><p>If Epivir is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis (see Zeffix SPC).</p><p>&nbsp;</p><p>Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered (see section 4.8).</p><p>&nbsp;</p><p><em>Paediatric population:</em> In a study performed in paediatric patients (see section 5.1 ARROW study), lower rates of virologic suppression and more frequent viral resistance were reported in children receiving the oral solution of Epivir as compared to those receiving the tablet formulation. Whenever possible in children, Epivir as tablet formulation should preferably be used.<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_a456c76e-1907-4836-92d8-32444047b645 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><em>Osteonecrosis:</em> Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p>&nbsp;</p><p><em>Drug Interactions:</em> Epivir should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine (see section 4.5).</p><p>&nbsp;</p><p>The combination of lamivudine with cladribine is not recommended (see section 4.5).</p><p>&nbsp;</p><p><em>Excipients: </em></p><p>Sodium: This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal clearance.</p><p>&nbsp;</p><p>Administration of trimethoprim/sulfamethoxazole 160&nbsp;mg/800&nbsp;mg results in a 40&nbsp;% increase in lamivudine exposure, because of the trimethoprim component; the sulfamethoxazole component did not interact. However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary (see section 4.2).&nbsp; Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulfamethoxazole.&nbsp; When concomitant administration is warranted, patients should be monitored clinically. Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of <em>Pneumocystis jirovecii</em> pneumonia (PCP) and toxoplasmosis should be avoided.</p><p>&nbsp;</p><p>The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when the main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine.&nbsp; The nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are unlikely to interact with lamivudine.</p><p>&nbsp;</p><p>A modest increase in C<sub>max </sub>(28&nbsp;%) was observed for zidovudine when administered with lamivudine, however overall exposure (AUC) is not significantly altered. Zidovudine has no effect on the pharmacokinetics of lamivudine (see section 5.2).</p><p>&nbsp;</p><p>Due to similarities, Epivir should not be administered concomitantly with other cytidine analogues, such as emtricitabine. Moreover, Epivir should not be taken with any other medicinal products containing lamivudine (see section 4.4).</p><p><em>In vitro</em> lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also support a possible interaction between lamivudine and cladribine. Therefore, the concomitant use of lamivudine with cladribine is not recommended (see section 4.4).</p><p>&nbsp;</p><p>Lamivudine metabolism does not involve CYP3A, making interactions with medicinal products metabolised by this system (e.g. PIs) unlikely.</p><p>&nbsp;</p><p>Coadministration of sorbitol solution (3.2&nbsp;g, 10.2&nbsp;g, 13.4&nbsp;g) with a single 300&nbsp;mg dose of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC<sub>&yen;</sub>) and 28%, 52%, and 55% in the C<sub>max </sub>of lamivudine in adults. When possible, avoid chronic coadministration of Epivir with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account.</p><p>Animal studies with lamivudine showed an increase in early embryonic deaths in rabbits but not in rats (see section 5.3). Placental transfer of lamivudine has been shown to occur in humans.</p><p>More than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure in pregnant women indicate no malformative and foeto/neonatal effect. Epivir can be used during pregnancy if clinically needed. The malformative risk is unlikely in humans based on those data.</p><p>For patients co-infected with hepatitis who are being treated with lamivudine and subsequently become pregnant, consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of lamivudine.</p><p><em>Mitochondrial dysfunction: </em>Nucleoside and nucleotide analogues have been demonstrated <em>in vitro</em> and <em>in vivo</em> to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in infants exposed <em>in utero</em> and/or post-natally to nucleoside analogues (see section 4.4).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Following oral administration lamivudine was excreted in breast milk at similar concentrations to those found in serum. Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (&lt; 4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24 weeks of age. There are no data available on the safety of lamivudine when administered to babies less than three months old. It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission of HIV.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Studies in animals showed that lamivudine had no effect on fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions have been reported during therapy for HIV disease with Epivir.&nbsp;</p><p>&nbsp;</p><p>The adverse reactions considered at least possibly related to the treatment are listed below by body system, organ class and absolute frequency. Frequencies are defined as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Blood and lymphatic systems disorders</p><p><em>Uncommon</em>: Neutropenia and anaemia (both occasionally severe), thrombocytopenia</p><p><em>Very rare</em>: Pure red cell aplasia</p><p>&nbsp;</p><p>Metabolism and nutrition disorders</p><p><em>Very rare</em>: Lactic acidosis</p><p>&nbsp;</p><p>Nervous system disorders</p><p><em>Common: </em>Headache, insomnia</p><p><em>Very rare:</em> Peripheral neuropathy (or paraesthesia)</p><p>&nbsp;</p><p>Respiratory, Thoracic and mediastinal disorders</p><p><em>Common:</em> Cough, nasal symptoms</p><p>&nbsp;</p><p>Gastrointestinal disorders</p><p><em>Common: </em>Nausea, vomiting, abdominal pain or cramps, diarrhoea</p><p><em>Rare:</em> Pancreatitis, elevations in serum amylase</p><p>&nbsp;</p><p>Hepatobiliary disorders</p><p><em>Uncommon:</em> Transient elevations in liver enzymes (AST, ALT)</p><p><em>Rare:</em> Hepatitis</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders</p><p><em>Common:</em> Rash, alopecia</p><p><em>Rare:</em> Angioedema</p><p>&nbsp;</p><p>Musculoskeletal and connective tissue disorders</p><p><em>Common: </em>Arthralgia,<strong> </strong>muscle disorders</p><p><em>Rare:</em> Rhabdomyolysis</p><p>&nbsp;</p><p>General disorders and administration site conditions</p><p><em>Common:</em> Fatigue, malaise, fever</p><p>&nbsp;</p><p>Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4)</p><p>&nbsp;</p><p>In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.&nbsp; Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).</p><p>&nbsp;</p><p>Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term combined antiretroviral exposure (CART). The frequency of which is unknown (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>1206 HIV-infected paediatric patients aged 3 months to 17 years were enrolled in the ARROW Trial (COL105677), 669 of whom received abacavir and lamivudine either once or twice daily (see section 5.1). No additional safety issues have been identified in paediatric subjects receiving either once or twice daily dosing compared to adults.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Reporting hotline: 19999</li><li>E-mail: <u>&nbsp;</u>npc.drug@sfda.gov.sa</li><li>Website: &nbsp;https://ade.sfda.gov.sa</li></ul><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: saudi.safety@gsk.com<u> </u></li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of lamivudine at very high dose levels in acute animal studies did not result in any organ toxicity.&nbsp; No specific signs or symptoms have been identified following acute overdose with lamivudine, apart from those listed as adverse reactions.</p><p>&nbsp;</p><p>If overdosage occurs the patient should be monitored, and standard supportive treatment applied as required.&nbsp; Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdosage, although this has not been studied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: nucleoside analogue, ATC Code: J05AF05.<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_6bb945a2-706e-45c6-aedb-854d1abe1f07 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). It is metabolised intracellularly to the active moiety, lamivudine 5&rsquo;-triphosphate. Its main mode of action is as a chain terminator of viral reverse transcription. The triphosphate has selective inhibitory activity against HIV-1 and HIV-2 replication <em>in vitro</em>,<em> </em>it is also active against zidovudine-resistant clinical isolates of HIV. No antagonistic effects <em>in vitro</em> were seen with lamivudine and other anti-retrovirals (tested agents: abacavir, didanosine, nevirapine and zidovudine).</p><p>&nbsp;</p><p><u>Resistance</u></p><p>HIV-1 resistance to lamivudine involves the development of a M184V amino acid change close to the active site of the viral reverse transcriptase (RT). This variant arises both <em>in vitro</em> and in HIV-1 infected patients treated with lamivudine-containing antiretroviral therapy. M184V mutants display greatly reduced susceptibility to lamivudine and show diminished viral replicative capacity <em>in vitro</em>.<em> In vitro</em> studies indicate that zidovudine-resistant virus isolates can become zidovudine sensitive when they simultaneously acquire resistance to lamivudine. The clinical relevance of such findings remains, however, not well defined.</p><p>&nbsp;</p><p><em>In vitro</em> data tend to suggest that the continuation of lamivudine in anti-retroviral regimen despite the development of M184V might provide residual anti-retroviral activity (likely through impaired viral fitness). The clinical relevance of these findings is not established. Indeed, the available clinical data are very limited and preclude any reliable conclusion in the field. In any case, initiation of susceptible NRTI&rsquo;s should always be preferred to maintenance of lamivudine therapy. Therefore, maintaining lamivudine therapy despite emergence of M184V mutation should only be considered in cases where no other active NRTI&rsquo;s are available.</p><p>&nbsp;</p><p>Cross-resistance conferred by the M184V RT is limited within the nucleoside inhibitor class of antiretroviral agents. Zidovudine and stavudine maintain their antiretroviral activities against lamivudine-resistant HIV-1. Abacavir maintains its antiretroviral activities against lamivudine-resistant HIV-1 harbouring only the M184V mutation. The M184V RT mutant shows a &lt;4-fold decrease in susceptibility to didanosine; the clinical significance of these findings is unknown. <em>In vitro</em> susceptibility testing has not been standardised and results may vary according to methodological factors.</p><p>&nbsp;</p><p>Lamivudine demonstrates low cytotoxicity to peripheral blood lymphocytes, to established lymphocyte and monocyte-macrophage cell lines, and to a variety of bone marrow progenitor cells <em>in vitro</em>.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>In clinical trials, lamivudine in combination with zidovudine<strong> </strong>has been shown to reduce HIV-1 viral load and increase CD4 cell count. Clinical end-point data indicate that lamivudine in combination with zidovudine, results in a significant reduction in the risk of disease progression and mortality.</p><p>&nbsp;</p><p>Evidence from clinical studies shows that lamivudine plus zidovudine<strong> </strong>delays the emergence of zidovudine resistant isolates in individuals with no prior antiretroviral therapy.</p><p>&nbsp;</p><p>Lamivudine has been widely used as a component of antiretroviral combination therapy with other antiretroviral agents of the same class (NRTIs) or different classes (PIs, non-nucleoside reverse transcriptase inhibitors).&nbsp;</p><p>&nbsp;</p><p>Clinical trial evidence from paediatric patients receiving lamivudine with other antiretroviral drugs (abacavir, nevirapine/efavirenz or zidovudine) has shown that the resistance profile observed in paediatric patients is similar to that observed in adults, in terms of the genotypic substitutions detected and their relative frequency.</p><p>&nbsp;</p><p>Children receiving lamivudine oral solution concomitantly with other antiretroviral oral solutions in clinical trials developed viral resistance more frequently than children receiving tablets (see the description of the clinical experience in paediatric population (ARROW study) and section 5.2).</p><p>&nbsp;</p><p>Multiple drug antiretroviral therapy containing lamivudine has been shown to be effective in antiretrovirally-naive patients as well as in patients presenting with viruses containing the M184V mutations.&nbsp;</p><p>&nbsp;</p><p>The relationship between <em>in vitro</em> susceptibility of HIV to lamivudine and clinical response to lamivudine-containing therapy remains under investigation.</p><p>&nbsp;</p><p>Lamivudine at a dose of 100&nbsp;mg once daily has also been shown to be effective for the treatment of adult patients with chronic HBV infection (for details of clinical studies, see the prescribing information for Zeffix). However, for the treatment of HIV infection only a 300&nbsp;mg daily dose of lamivudine (in combination with other antiretroviral agents) has been shown to be efficacious.</p><p>&nbsp;</p><p>Lamivudine has not been specifically investigated in HIV patients co-infected with HBV.</p><p>&nbsp;</p><p><em>Once daily dosing (300&nbsp;mg once a day):</em> a clinical study has demonstrated the non-inferiority between Epivir once a day and Epivir twice a day containing regimens. These results were obtained in an antiretroviral na&iuml;ve population, primarily consisting of asymptomatic HIV infected patients (CDC stage A).</p><p>&nbsp;</p><p><em>Paediatric population: </em>a randomised comparison of a regimen including once daily vs twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients. 1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006). After 36 weeks on a regimen including twice daily abacavir and lamivudine, 669 eligible subjects were randomised to either continue twice daily dosing or switch to once daily abacavir and lamivudine for at least 96 weeks. Of note, from this study clinical data were not available for children under one year old. The results are summarised in the table below:</p><p><strong>Virological Response Based on Plasma HIV-1 RNA less than 80 copies/ml at Week 48 and Week 96 in the Once Daily versus Twice Daily abacavir + lamivudine randomisation of ARROW (Observed Analysis)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:456px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Twice Daily</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Once Daily</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week 0 (After &ge;36 Weeks on Treatment)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma HIV-1 RNA &lt;80 c/ml</p></td><td style="vertical-align:top"><p>250/331 (76)</p></td><td style="vertical-align:top"><p>237/335 (71)</p></td></tr><tr><td style="vertical-align:top"><p>Risk difference (once daily-twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>-4.8% (95% CI -11.5% to +1.9%), p=0.16</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma HIV-1 RNA &lt;80 c/ml</p></td><td style="vertical-align:top"><p>242/331 (73)</p></td><td style="vertical-align:top"><p>236/330 (72)</p></td></tr><tr><td style="vertical-align:top"><p>Risk difference (once daily-twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>-1.6% (95% CI -8.4% to +5.2%), p=0.65</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week 96</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma HIV-1 RNA &lt;80 c/ml</p></td><td style="vertical-align:top"><p>234/326 (72)</p></td><td style="vertical-align:top"><p>230/331 (69)</p></td></tr><tr><td style="vertical-align:top"><p>Risk difference (once daily-twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>-2.3% (95% CI -9.3% to +4.7%), p=0.52</p></td></tr></tbody></table><p>&nbsp;</p><p>In a pharmacokinetic study (PENTA 15), four virologically controlled subjects less than 12 months of age switched from abacavir plus lamivudine oral solution twice daily to a once daily regimen. Three subjects had undetectable viral load and one had plasmatic HIV-RNA of 900 copies/ml at Week 48. No safety concerns were observed in these subjects.</p><p>&nbsp;</p><p>The abacavir + lamivudine once daily dosing group was demonstrated to be non-inferior to the twice daily group according to the pre-specified non-inferiority margin of -12%, for the primary endpoint of &lt;80 c/ml at Week 48 as well as at Week 96 (secondary endpoint) and all other thresholds tested (&lt;200c/ml, &lt;400c/ml, &lt;1000c/ml), which all fell well within this non-inferiority margin. Subgroup analyses testing for heterogeneity of once vs twice daily demonstrated no significant effect of sex, age, or viral load at randomisation. Conclusions supported non-inferiority regardless of analysis method.</p><p>&nbsp;</p><p>At the time of randomization to once daily vs twice daily dosing (Week 0), those patients who had received tablet formulations had a higher rate of viral load suppression than those who had received any solution formulations at any time. These differences were observed in each different age group studied. This difference in suppression rates between tablets and solutions remained through Week 96 with once daily dosing.</p><p>&nbsp;</p><p><strong>Proportions of Subjects in the Once Daily versus Twice Daily Abacavir+Lamivudine Randomisation of ARROW with Plasma HIV-1 RNA &lt;80 copies/ml: Subgroup Analysis by Formulation</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:559px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Twice Daily</p><p>Plasma HIV-1 RNA &lt;80&nbsp;c/ml:<br />n/N (%)</p></td><td style="vertical-align:top"><p>Once Daily</p><p>Plasma HIV-1 RNA &lt;80&nbsp;c/ml:<br />n/N (%)</p></td></tr><tr><td style="vertical-align:top"><p>Week 0 (after 36 weeks on Treatment)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Any solution regimen at any time</p></td><td style="vertical-align:top"><p>14/26 (54)</p></td><td style="vertical-align:top"><p>15/30 (50)</p></td></tr><tr><td style="vertical-align:top"><p>All tablet based regimen throughout</p></td><td style="vertical-align:top"><p>236/305 (77)</p></td><td style="vertical-align:top"><p>222/305 (73)</p></td></tr><tr><td style="vertical-align:top"><p>Week 96</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Any solution regimen at any time</p></td><td style="vertical-align:top"><p>13/26 (50)</p></td><td style="vertical-align:top"><p>17/30 (57)</p></td></tr><tr><td style="vertical-align:top"><p>All tablet based regimen throughout</p></td><td style="vertical-align:top"><p>221/300 (74)</p></td><td style="vertical-align:top"><p>213/301 (71)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Genotypic resistance analyses were conducted on samples with plasma HIV-1 RNA &gt;1000 copies/ml. More cases of resistance were detected among patients who had received lamivudine solution, in combination with other antiretroviral solutions, compared with those who received similar doses of tablet formulation. This is consistent with the lower rates of antiviral suppression observed in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><em>&nbsp;</em></p><p>Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85%.&nbsp; Following oral administration, the mean time (t<sub>max</sub>) to maximal serum concentrations (C<sub>max</sub>) is about an hour. Based on data derived from a study in healthy volunteers, at a therapeutic dose of 150 mg twice daily, mean (CV) steady-state C<sub>max</sub> and C<sub>min</sub> of lamivudine in plasma are 1.2 &micro;g/ml (24%) and 0.09 &micro;g/ml (27%), respectively.&nbsp; The mean (CV) AUC over a dosing interval of 12 hours is 4.7 &micro;g.h/ml (18%).&nbsp; At a therapeutic dose of 300&nbsp;mg once daily, the mean (CV) steady-state C<sub>max</sub>, C<sub>min</sub> and 24h AUC are 2.0 &micro;g/ml (26%), 0.04 &micro;g/ml (34%) and 8.9 &micro;g.h/ml (21%), respectively.</p><p>&nbsp;</p><p>The 150&nbsp;mg tablet is bioequivalent and dose proportional to the 300&nbsp;mg tablet with respect to AUC<sub>&yen;</sub>, C<sub>max</sub>, and t<sub>max</sub><strong>.</strong> Administration of Epivir tablets is bioequivalent to Epivir oral solution with respect to AUC<sub>&infin;</sub> and C<sub>max</sub> in adults. Absorption differences have been observed between adult and paediatric populations (see Special populations).</p><p>&nbsp;</p><p>Co-administration of lamivudine with food results in a delay of t<sub>max</sub> and a lower C <sub>max</sub> (decreased by 47%). However, the extent (based on the AUC) of lamivudine absorbed is not influenced.&nbsp;</p><p>&nbsp;</p><p>Administration of crushed tablets with a small amount of semi-solid food or liquid would not be expected to have an impact on the pharmaceutical quality, and would therefore not be expected to alter the clinical effect.&nbsp; This conclusion is based on the physiochemical and pharmacokinetic data assuming that the patient crushes and transfers 100% of the tablet and ingests immediately.</p><p>&nbsp;</p><p>Co-administration of zidovudine results in a 13% increase in zidovudine exposure and a 28&nbsp;% increase in peak plasma levels.&nbsp; This is not considered to be of significance to patient safety and therefore no dosage adjustments are necessary.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><em>&nbsp;</em></p><p>From intravenous studies, the mean volume of distribution is 1.3&nbsp;l/kg.&nbsp; &nbsp;The mean systemic clearance of lamivudine is approximately<br />0.32&nbsp;l/h/kg, with predominantly renal clearance (&gt; 70%) via the organic cationic transport system.</p><p>&nbsp;</p><p>Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin (&lt; 16% - 36% to serum albumin in <em>in vitro</em> studies).</p><p>&nbsp;</p><p>Limited data show that lamivudine penetrates the central nervous system and reaches the cerebro-spinal fluid (CSF).&nbsp; The mean ratio CSF/serum lamivudine concentration 2-4 hours after oral administration was approximately 0.12.&nbsp; The true extent of penetration or relationship with any clinical efficacy is unknown.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>&nbsp;</em></p><p>The plasma lamivudine half-life after oral dosing is 18 to 19 hours and the active moiety, intracellular lamivudine triphosphate, has a prolonged terminal half-life in the cell (16 to 19 hours).&nbsp; In 60 healthy adult volunteers, Epivir 300&nbsp;mg once daily has been demonstrated to be pharmacokinetically equivalent at steady-state to Epivir 150&nbsp;mg twice daily with respect to intracellular triphosphate AUC<sub>24</sub> and C<sub>max</sub>.</p><p>&nbsp;</p><p>Lamivudine is predominately cleared unchanged by renal excretion. The likelihood of metabolic interactions of lamivudine with other medicinal products is low due to the small extent of hepatic metabolism (5-10%) and low plasma protein binding.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><em>&nbsp;</em></p><p>Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. A recommended dosage regimen for patients with creatinine clearance below 50&nbsp;ml/min is shown in the dosage section (see section 4.2).</p><p>&nbsp;</p><p>An interaction with trimethoprim, a constituent of co-trimoxazole, causes a 40% increase in lamivudine exposure at therapeutic doses.&nbsp; This does not require dose adjustment unless the patient also has renal impairment (see sections 4.5 and 4.2).&nbsp; Administration of co-trimoxazole with lamivudine in patients with renal impairment should be carefully assessed.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Children:</em> The absolute bioavailability of lamivudine (approximately 58-66%) was reduced in paediatric patients below 12 years of age.&nbsp; In children, administration of tablets given concomitantly with other antiretroviral tablets delivered higher plasma lamivudine AUC<sub>&infin;</sub> and C<sub>max</sub> than oral solution given concomitantly with other antiretroviral oral solutions. Children receiving lamivudine oral solution according to the recommended dosage regimen achieve plasma lamivudine exposure within the range of values observed in adults.&nbsp; Children receiving lamivudine oral tablets according to the recommended dosage regimen achieve higher plasma lamivudine exposure than children receiving oral solution because higher mg/kg doses are administered with the tablet formulation and the tablet formulation has higher bioavailability (see section 4.2). Paediatric pharmacokinetic studies with both oral solution and tablet formulations have demonstrated that once daily dosing provides equivalent AUC<sub>0-24 </sub>to twice daily dosing of the same total daily dose.</p><p>&nbsp;</p><p>There are limited pharmacokinetic data for patients less than three months of age. In neonates one week of age, lamivudine oral clearance was reduced when compared to paediatric patients and is likely to be due to immature renal function and variable absorption.&nbsp; Therefore to achieve similar adult and paediatric exposure, an appropriate dose for neonates is 4&nbsp;mg/kg/day. Glomerular filtration estimates suggests that to achieve similar adult and paediatric exposure, an appropriate dose for children aged six weeks and older could be 8&nbsp;mg/kg/day.</p><p>&nbsp;</p><p>Pharmacokinetic data were derived from 3 pharmacokinetic studies (PENTA 13, PENTA 15 and ARROW PK substudy) enrolling children under 12 years of age. The data are displayed in the table below:</p><p>&nbsp;</p><p><strong>Summary of Stead-State Plasma Lamivudine AUC (0-24) (&micro;</strong><strong>g.h/ml) and Statistical Comparisons for Once and Twice-Daily Oral Administration Across Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Age Group</strong></p></td><td style="vertical-align:top"><p><strong>Lamivudine </strong></p><p><strong>8mg/kg Once-Daily Dosing Geometric Mean (95% Cl)</strong></p></td><td style="vertical-align:top"><p><strong>Lamivudine</strong></p><p><strong>4 mg/kg Twice-Daily Dosing Geometric Mean (95% Cl)</strong></p></td><td style="vertical-align:top"><p><strong>Once-Versus Twice-Daily Comparison GLS Mean Ratio (90% Cl)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ARROW PK Substudy</p><p>Part 1</p></td><td style="vertical-align:top"><p>3 to 12 years (N=35)</p></td><td style="vertical-align:top"><p>13.0</p><p>(11.4,14.9)</p></td><td style="vertical-align:top"><p>12.0</p><p>(10.7, 13.4)</p></td><td style="vertical-align:top"><p>1.09</p><p>(0.979, 1.20)</p></td></tr><tr><td style="vertical-align:top"><p>PENTA 13</p></td><td style="vertical-align:top"><p>2 to 12 years (N=19)</p></td><td style="vertical-align:top"><p>9.80</p><p>(8.64, 11.1)</p></td><td style="vertical-align:top"><p>8.88</p><p>(7.67, 10.3)</p></td><td style="vertical-align:top"><p>1.12</p><p>(1.03, 1.21)</p></td></tr><tr><td style="vertical-align:top"><p>PENTA 15</p></td><td style="vertical-align:top"><p>3 to 36 months (N=17)</p></td><td style="vertical-align:top"><p>8.66</p><p>(7.46, 10.1)</p></td><td style="vertical-align:top"><p>9.48</p><p>(7.89, 11.40)</p></td><td style="vertical-align:top"><p>0.91</p><p>(0.79, 1.06)</p></td></tr></tbody></table><p>&nbsp;</p><p>In PENTA 15 study, the geometric mean plasma lamivudine AUC(0-24) (95% CI) of the four subjects under 12 months of age who switch from a twice daily to a once daily regimen (see section 5.1) are 10.31 (6.26, 17.0) &micro;g.h/ml in the once-daily dosing and 9.24 (4.66, 18.3) &micro;g.h/ml in the twice-daily dosing.</p><p>&nbsp;</p><p><em>Pregnancy:</em><strong> </strong>Following oral administration, lamivudine pharmacokinetics in late-pregnancy were similar to non-pregnant women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of lamivudine in animal toxicity studies at high doses was not associated with any major organ toxicity.&nbsp; At the highest dosage levels, minor effects on indicators of liver and kidney function were seen together with occasional reductions in liver weight.&nbsp; The clinically relevant effects noted were a reduction in red blood cell count and neutropenia.</p><p>&nbsp;</p><p>Lamivudine was not mutagenic in bacterial tests but, like many nucleoside analogues, showed activity in an <em>in vitro </em>cytogenetic assay and the mouse lymphoma assay.&nbsp; Lamivudine was not genotoxic <em>in vivo</em> at doses that gave plasma concentrations around 40-50 times higher than the anticipated clinical plasma levels. As the <em>in vitro</em> mutagenic activity of lamivudine could not be confirmed in <em>in vivo</em> tests, it is concluded that lamivudine should not represent a genotoxic hazard to patients undergoing treatment.</p><p>&nbsp;</p><p>A transplacental genotoxicity study conducted in monkeys compared zidovudine alone with the combination of zidovudine and lamivudine at human-equivalent exposures.&nbsp; The study demonstrated that foetuses exposed <em>in utero</em> to the combination sustained a higher level of nucleoside analogue-DNA incorporation into multiple foetal organs, and showed evidence of more telomere shortening than in those exposed to zidovudine alone. The clinical significance of these findings is unknown.</p><p>&nbsp;</p><p>The results of long-term carcinogenicity studies in rats and mice did not show any carcinogenic potential relevant for humans.</p><p>&nbsp;</p><p>A fertility study in rats has shown that lamivudine had no effect on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core:</em></p><p>Microcrystalline cellulose (E460),</p><p>Sodium starch glycollate</p><p>Magnesium stearate</p><p><em>&nbsp;</em></p><p><em>Tablet film-coat:</em></p><p>Hypromellose (E464)</p><p>Titanium dioxide (E171),</p><p>Macrogol,</p><p>Polysorbate 80</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C<!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_2219c4c2-0dc4-42ab-9f69-48ed88b0d80d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartons containing tablets in a white high density polyethylene (HDPE) bottle, with a child-resistant closure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Not all pack sizes are marketed in every country.</p><p><em>Epivir</em> is a trademark owned by or licenced to the ViiV Healthcare group of companies.</p><p>&copy; 2023 ViiV Healthcare group of companies. All rights reserved</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Delpharm Poznań Spółka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland 

Marketing Authorisation Holder:
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia
*member of the GSK group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version Number: UK_12
Date of Revision of the Text: 21 April 2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>